Frazier Life Sciences Management, L.P.: TREVI THERAPEUTICS INC (TRVI): Quarterly 13F Position History
As of Q1 2026, Frazier Life Sciences Management, L.P. reported 9,939,547 shares of TREVI THERAPEUTICS INC (TRVI), worth $118.6M and representing 3.1% of its 13F equity book. Quarter-over-quarter share count change: 319,862 (-3.1%) . The position first appeared in Q2 2022 and has been disclosed across 16 13F-HR filings in Pactolio's tracked window.
- 9,939,547Shares Held (Latest Filing)
- $118.6MReported Market Value (Latest Filing)
- 3.1%Portfolio Weight (% of 13F Equity Book)
- 319,862Quarter-over-Quarter Share Change
- -$9.9MQuarter-over-Quarter Value Change
- 10,664,774Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 16 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 9,939,547 | 319,862 | -3.1% | $118.6M | 3.1% | $11.9 |
| Q4 2025 | 10,259,409 | 0 | — | $128.4M | 3.5% | $12.5 |
| Q3 2025 | 10,259,409 | 0 | — | $93.9M | 2.8% | $9.2 |
| Q2 2025 | 10,259,409 | 0 | — | $56.1M | 2.2% | $5.5 |
| Q1 2025 | 10,259,409 | 405,365 | -3.8% | $64.5M | 2.9% | $6.3 |
| Q4 2024 | 10,664,774 | +3,283,684 | +44.5% | $43.9M | 1.8% | $4.1 |
| Q3 2024 | 7,381,090 | 0 | — | $24.7M | 1.0% | $3.3 |
| Q2 2024 | 7,381,090 | 0 | — | $22.0M | 1.0% | $3.0 |
| Q1 2024 | 7,381,090 | 0 | — | $25.5M | 1.1% | $3.5 |
| Q4 2023 | 7,381,090 | +500,000 | +7.3% | $9.9M | 0.5% | $1.3 |
| Q3 2023 | 6,881,090 | 0 | — | $15.0M | 1.0% | $2.2 |
| Q2 2023 | 6,881,090 | +217,500 | +3.3% | $16.4M | 1.0% | $2.4 |
| Q1 2023 | 6,663,590 | 0 | — | $12.3M | 0.9% | $1.9 |
| Q4 2022 | 6,663,590 | +1,260,000 | +23.3% | $12.9M | 0.8% | $1.9 |
| Q3 2022 | 5,403,590 | +4,231,963 | +361.2% | $8.3M | 0.6% | $1.5 |
| Q2 2022 | 1,171,627 | — | — | $3.3M | 0.3% | $2.8 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a TRVI position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported TREVI THERAPEUTICS INC (TRVI) on its 13F-HR filing for the period ending 2022-06-30 (Q2 2022). The position has appeared on 16 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in TRVI?
Between Q4 2025 and Q1 2026, Frazier Life Sciences Management, L.P. reduced its TRVI position by 319,862 shares (-3.1%), leaving 9,939,547 shares at a market value of $118.6M.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in TRVI?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.